These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

115 related items for PubMed ID: 11780723

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Vascular endothelial growth factor enhances glomerular capillary repair and accelerates resolution of experimentally induced glomerulonephritis.
    Masuda Y, Shimizu A, Mori T, Ishiwata T, Kitamura H, Ohashi R, Ishizaki M, Asano G, Sugisaki Y, Yamanaka N.
    Am J Pathol; 2001 Aug; 159(2):599-608. PubMed ID: 11485918
    [Abstract] [Full Text] [Related]

  • 5. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice.
    Brekken RA, Overholser JP, Stastny VA, Waltenberger J, Minna JD, Thorpe PE.
    Cancer Res; 2000 Sep 15; 60(18):5117-24. PubMed ID: 11016638
    [Abstract] [Full Text] [Related]

  • 6. Expression of vascular endothelial growth factor and its receptors in rats with protein-overload nephrosis.
    Horita Y, Miyazaki M, Koji T, Kobayashi N, Shibuya M, Razzaque MS, Cheng M, Ozono Y, Kohno S, Taguchi T.
    Nephrol Dial Transplant; 1998 Oct 15; 13(10):2519-28. PubMed ID: 9794554
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Ultrastructural localization of the vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) receptor-2 (FLK-1, KDR) in normal mouse kidney and in the hyperpermeable vessels induced by VPF/VEGF-expressing tumors and adenoviral vectors.
    Feng D, Nagy JA, Brekken RA, Pettersson A, Manseau EJ, Pyne K, Mulligan R, Thorpe PE, Dvorak HF, Dvorak AM.
    J Histochem Cytochem; 2000 Apr 15; 48(4):545-56. PubMed ID: 10727296
    [Abstract] [Full Text] [Related]

  • 10. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant.
    Millauer B, Shawver LK, Plate KH, Risau W, Ullrich A.
    Nature; 1994 Feb 10; 367(6463):576-9. PubMed ID: 8107827
    [Abstract] [Full Text] [Related]

  • 11. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins.
    Aiello LP, Pierce EA, Foley ED, Takagi H, Chen H, Riddle L, Ferrara N, King GL, Smith LE.
    Proc Natl Acad Sci U S A; 1995 Nov 07; 92(23):10457-61. PubMed ID: 7479819
    [Abstract] [Full Text] [Related]

  • 12. VEGF is an essential molecule for glomerular structuring.
    Kitamoto Y, Tokunaga H, Miyamoto K, Tomita K.
    Nephrol Dial Transplant; 2002 Nov 07; 17 Suppl 9():25-7. PubMed ID: 12386279
    [Abstract] [Full Text] [Related]

  • 13. Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis.
    Binétruy-Tournaire R, Demangel C, Malavaud B, Vassy R, Rouyre S, Kraemer M, Plouët J, Derbin C, Perret G, Mazié JC.
    EMBO J; 2000 Apr 03; 19(7):1525-33. PubMed ID: 10747021
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro.
    Tille JC, Wood J, Mandriota SJ, Schnell C, Ferrari S, Mestan J, Zhu Z, Witte L, Pepper MS.
    J Pharmacol Exp Ther; 2001 Dec 03; 299(3):1073-85. PubMed ID: 11714897
    [Abstract] [Full Text] [Related]

  • 16. Vascular endothelial growth factor as a marker of tumor endothelium.
    Brekken RA, Huang X, King SW, Thorpe PE.
    Cancer Res; 1998 May 01; 58(9):1952-9. PubMed ID: 9581838
    [Abstract] [Full Text] [Related]

  • 17. Vascular endothelial growth factor is an essential molecule for mouse kidney development: glomerulogenesis and nephrogenesis.
    Kitamoto Y, Tokunaga H, Tomita K.
    J Clin Invest; 1997 May 15; 99(10):2351-7. PubMed ID: 9153276
    [Abstract] [Full Text] [Related]

  • 18. VEGF via VEGF receptor-1 (Flt-1) mimics preeclamptic plasma in inhibiting uterine blood vessel relaxation in pregnancy: implications in the pathogenesis of preeclampsia.
    Brockelsby J, Hayman R, Ahmed A, Warren A, Johnson I, Baker P.
    Lab Invest; 1999 Sep 15; 79(9):1101-11. PubMed ID: 10496528
    [Abstract] [Full Text] [Related]

  • 19. Targeting vascular endothelial growth factor blockade: ascites and pleural effusion formation.
    Verheul HM, Hoekman K, Jorna AS, Smit EF, Pinedo HM.
    Oncologist; 2000 Sep 15; 5 Suppl 1():45-50. PubMed ID: 10804091
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of vascular endothelial growth factor induced mitogenesis of human endothelial cells by a chimeric anti-kinase insert domain-containing receptor antibody.
    Zhu Z, Lu D, Kotanides H, Santiago A, Jimenez X, Simcox T, Hicklin DJ, Bohlen P, Witte L.
    Cancer Lett; 1999 Mar 01; 136(2):203-13. PubMed ID: 10355750
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.